ERBB2 and breast cancer: These results differ from previous studies in second-line mBC that did not show an association between PIK3CA mutation and efficacy in T-DM1-treated patients with HER2-positive breast cancer, suggesting that T-DM1 treatment may overcome the prognostic value of PIK3CA mutations [13].